Opportunity Information: Apply for RFA DK 10 008
Apply for RFA DK 10 008
- The National Institutes of Health in the food and nutrition health income security and social services sector is offering a public funding opportunity titled "Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D). Towards an Artificial Pancreas (SBIR) (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on May 19, 2010 and posted on May 19, 2010.
- Applicants must submit their applications by Nov 29, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,200,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D). Towards an Artificial Pancreas (SBIR) (R43/R44)" is a National Institutes of Health (NIH) funding announcement aimed specifically at small business concerns that are developing new technologies to improve care for people with type 1 diabetes. The central focus is progress toward an artificial pancreas, meaning a long-term, integrated system that can automatically regulate blood glucose by continuously sensing glucose levels and delivering insulin in a glucose-responsive way. In practical terms, the program is looking for innovative therapeutics, monitoring tools, and related components that can move the field closer to a reliable closed-loop or fully integrated glucose-regulated insulin delivery system.
This opportunity uses the Small Business Innovation Research (SBIR) mechanism, specifically the R43/R44 formats, which are designed to help small companies translate early-stage ideas into workable prototypes and, ultimately, products with real-world clinical potential. The announcement allows Phase I applications (generally for early feasibility and proof-of-concept work), Phase II applications (for more advanced development and validation), and Fast Track applications (a combined Phase I/Phase II submission intended to speed progression when there is a clear development path). The intent behind offering all three options is to support innovations at different maturity levels, from initial technical feasibility through more mature development efforts that could be positioned for commercialization and eventual use in diabetes management.
Funding for this specific solicitation was estimated at $3.2 million for fiscal year 2011, with an expectation of making roughly 5 to 10 awards. The number of awards and future year funding levels were noted as dependent on annual appropriations, meaning NIH anticipated supporting a cohort of projects but could adjust based on the federal budget. Importantly, there is no cost sharing or matching requirement, which can make participation more feasible for small companies that might otherwise struggle to provide significant non-federal matching funds.
Eligibility is limited to small businesses, consistent with the SBIR program rules. The opportunity is categorized as a discretionary grant, with activity areas that align with health-related research and development. It is associated with CFDA numbers 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) and 93.865 (Child Health and Human Development Extramural Research), reflecting the NIH institutes and research portfolios most closely connected to diabetes technology development and related health impacts.
Administratively, the announcement is identified by Funding Opportunity Number RFA-DK-10-008. It was posted on May 19, 2010, with an original and current closing date of November 29, 2010, and an archive date of December 30, 2010, indicating that it was a time-limited solicitation active during that period. The sponsoring agency is NIH, and the full announcement was hosted through the NIH grants guide. For access issues or broken links, the listed point of contact was the NIH Office of Extramural Research (OER) webmaster via FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions
What is the title of this grant opportunity?
The opportunity is titled "Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D). Towards an Artificial Pancreas (SBIR) (R43/R44)."
Which federal agency is offering this funding opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What is the main goal of this SBIR solicitation?
The central goal is to support small businesses developing new technologies that improve care for people with type 1 diabetes, with a specific emphasis on progress toward an artificial pancreas.
What does "towards an artificial pancreas" mean in this announcement?
It refers to advancing a long-term, integrated system that can automatically regulate blood glucose by continuously sensing glucose levels and delivering insulin in a glucose-responsive way. In practical terms, it points to work that helps enable a reliable closed-loop or fully integrated glucose-regulated insulin delivery system.
What types of projects is NIH looking to fund under this announcement?
The program is looking for innovative therapeutics, monitoring tools, and related components that can move the field closer to a closed-loop or fully integrated system for glucose-regulated insulin delivery.
What funding mechanism is used for this opportunity?
This opportunity uses the Small Business Innovation Research (SBIR) mechanism, specifically the R43/R44 formats.
What do R43 and R44 refer to?
R43 and R44 are SBIR award formats used by NIH to support small companies as they translate early-stage ideas into workable prototypes and ultimately products with real-world clinical potential.
Which application options are allowed (Phase I, Phase II, Fast Track)?
The announcement allows Phase I applications, Phase II applications, and Fast Track applications (a combined Phase I/Phase II submission).
What is Phase I intended to support?
Phase I is generally intended for early feasibility and proof-of-concept work.
What is Phase II intended to support?
Phase II is intended for more advanced development and validation efforts.
What is a Fast Track application in this context?
Fast Track is a combined Phase I/Phase II submission intended to speed progression when there is a clear development path from feasibility through more advanced development.
Who is eligible to apply?
Eligibility is limited to small business concerns, consistent with SBIR program rules.
Is cost sharing or matching required?
No. The solicitation states there is no cost sharing or matching requirement.
How much funding was estimated for this solicitation?
Funding was estimated at $3.2 million for fiscal year 2011.
How many awards did NIH expect to make?
NIH anticipated making roughly 5 to 10 awards.
Are the number of awards and future funding levels guaranteed?
No. The announcement noted that the number of awards and future year funding levels depended on annual appropriations.
What type of grant is this categorized as?
It is categorized as a discretionary grant.
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) and 93.865 (Child Health and Human Development Extramural Research).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-DK-10-008.
When was the opportunity posted?
It was posted on May 19, 2010.
What were the closing date and archive date?
The original and current closing date was November 29, 2010, and the archive date was December 30, 2010.
Was this a time-limited solicitation?
Yes. The listed closing and archive dates indicate it was active during a defined period in 2010.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide.
Who should be contacted for access issues or broken links?
For access issues or broken links, the listed point of contact was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more business programs for Business Consultants, Innovation Research Organizations, Business Innovation, Diabetes Research
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health Income Security and Social Services
Next opportunity: TONOPAH BOOTSTRAPS FOR LOCAL YOUNG ADULTS
Previous opportunity: WHITE RIVER VALLEY INVASIVE WEEDS SNPLMA PROJECT
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 10 008
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 10 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R01) Apply for PAR 10 230 Funding Number: PAR 10 230 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R21) Apply for PAR 10 232 Funding Number: PAR 10 232 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| A GenitoUrinary Development Molecular Anatomy Project (GUDMAP) Database and Website (U01) Apply for RFA DK 10 005 Funding Number: RFA DK 10 005 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Lifestyle Interventions in Overweight and Obese Pregnant Women Consortium (U01) Apply for RFA DK 10 014 Funding Number: RFA DK 10 014 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Feasibility Studies for Clinical Trials in Type 1 Diabetes (R03) Apply for RFA DK 11 007 Funding Number: RFA DK 11 007 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $50,000 |
| Clinical Trial Planning Grants in Type 1 Diabetes (R34) Apply for RFA DK 11 010 Funding Number: RFA DK 11 010 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 10 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.